Investors have decided longevity clinics are the future of preventative care, but physicians are still waiting for proof. It's one of the conversations we'll be following at HLTH this year.
Take Neko Health: its US expansion already has a waitlist of more than 350,000 people. But Prenuvo, one of its competitors, is facing a high-profile malpractice suit from a customer who paid $2,500 for a whole-body MRI and then had a stroke the scan allegedly missed predicting.
In 2026, these preventive clinics have answered by partnering with companies that have clinical research behind them:
- Superpower added GRAIL's Galleri multi-cancer test as a paid add-on in April
- Human Longevity and Insilico Medicine are building a joint foundation model aimed at predicting disease decades out
- Neko and Neuralink are reportedly piloting a screening pipeline for Neuralink's spinal-injury trial
These partnerships are about borrowing evidence. Each partner has had to answer to a regulator, a reviewer, or a trial registry (exactly what the clinics have skipped), implying that physician skepticism is warranted. Also, collecting that data in-house would take longer than the current wave of demand will last.
Track the trends shaping healthy aging and longevity in the Insights Hub we built with HLTH. It'll get you smart on every tech player heading to HLTH USA 2026. Register with CBI's code H26PAR_CBI250 to save $1,050 before prices go up on September 12th.